Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GMTX Gemini Therapeutics	$60.35 +1.0%	$56.73	$1.16 ▼ $14.10	$2.61B	-0.12	189,291 shs	349,244 shs
IMVT Immunovant	$14.90 -2.3%	$16.38	$12.72 ▼ $34.47	$2.59B	0.66	1.46 million shs	614,356 shs
MRVI Maravai LifeSciences	$2.41 -1.8%	$2.45	$1.66 ▼ $9.60	$614.14M	0.28	2.39 million shs	708,586 shs
RXRX Recursion Pharmaceuticals	$4.85 -1.9%	$5.46	$3.79 ▼ $12.36	$2.10B	0.93	24.73 million shs	13.64 million shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GMTX Gemini Therapeutics	0.00%	+0.82%	-0.38%	+27.40%	+22.14%
IMVT Immunovant	0.00%	+0.13%	-10.09%	+5.39%	-52.99%
MRVI Maravai LifeSciences	0.00%	-6.13%	-8.92%	+10.36%	-72.50%
RXRX Recursion Pharmaceuticals	0.00%	-14.38%	-23.88%	+21.08%	-36.75%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IMVT Immunovant	2.927 of 5 stars	4.4	2.0	0.0	0.0	2.6	1.7	0.0
MRVI Maravai LifeSciences	4.0087 of 5 stars	3.1	3.0	0.0	4.4	2.9	0.8	0.6
RXRX Recursion Pharmaceuticals	2.3464 of 5 stars	3.2	1.0	0.0	0.0	3.2	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GMTX Gemini Therapeutics	0.00	N/A	N/A	N/A
IMVT Immunovant	2.83	Moderate Buy	$35.20	136.31% Upside
MRVI Maravai LifeSciences	2.25	Hold	$5.75	139.09% Upside
RXRX Recursion Pharmaceuticals	2.33	Hold	$7.00	44.48% Upside

Current Analyst Ratings Breakdown

Latest MRVI, IMVT, GMTX, and RXRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	IMVT Immunovant	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$40.00 ➝ $37.00
8/12/2025	IMVT Immunovant	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$33.00 ➝ $30.00
8/12/2025	MRVI Maravai LifeSciences	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$7.00 ➝ $5.00
8/11/2025	IMVT Immunovant	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
7/28/2025	IMVT Immunovant	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$17.00 ➝ $18.00
7/10/2025	IMVT Immunovant	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold	$18.00
7/8/2025	RXRX Recursion Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
7/3/2025	RXRX Recursion Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Equal Weight	$5.00
6/16/2025	RXRX Recursion Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$8.00 ➝ $5.00

(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	$2.89 per share	N/A
IMVT Immunovant	N/A	N/A	N/A	N/A	$4.16 per share	N/A
MRVI Maravai LifeSciences	$259.18M	2.37	$0.61 per share	3.96	$2.28 per share	1.05
RXRX Recursion Pharmaceuticals	$58.84M	35.75	N/A	N/A	$2.61 per share	1.86

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GMTX Gemini Therapeutics	-$71.87M	-$1.00	N/A	N/A	N/A	N/A	-38.78%	-35.88%	N/A
IMVT Immunovant	-$413.84M	-$2.85	N/A	N/A	N/A	N/A	-80.99%	-72.23%	11/6/2025 (Estimated)
MRVI Maravai LifeSciences	-$144.85M	-$1.36	N/A	N/A	N/A	-90.03%	-17.60%	-9.30%	11/6/2025 (Estimated)
RXRX Recursion Pharmaceuticals	-$463.66M	-$1.78	N/A	N/A	N/A	-1,004.91%	-76.09%	-54.29%	11/5/2025 (Estimated)

Latest MRVI, IMVT, GMTX, and RXRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q1 2026	IMVT Immunovant	-$0.69	-$0.60	+$0.09	-$0.71	N/A	N/A
8/5/2025	Q2 2025	RXRX Recursion Pharmaceuticals	-$0.35	-$0.41	-$0.06	-$0.41	$15.38 million	$19.10 million
5/29/2025	Q4 2025	IMVT Immunovant	-$0.72	-$0.64	+$0.08	-$0.64	N/A	$0.16 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	N/A
IMVT Immunovant	N/A	N/A	N/A	N/A	N/A
MRVI Maravai LifeSciences	N/A	N/A	N/A	N/A	N/A
RXRX Recursion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GMTX Gemini Therapeutics	N/A	71.49	71.49
IMVT Immunovant	N/A	12.32	12.32
MRVI Maravai LifeSciences	0.68	5.16	4.49
RXRX Recursion Pharmaceuticals	0.02	3.58	3.58

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GMTX Gemini Therapeutics	75.42%
IMVT Immunovant	47.08%
MRVI Maravai LifeSciences	50.25%
RXRX Recursion Pharmaceuticals	89.06%

Insider Ownership

Company	Insider Ownership
GMTX Gemini Therapeutics	12.90%
IMVT Immunovant	1.80%
MRVI Maravai LifeSciences	2.11%
RXRX Recursion Pharmaceuticals	8.43%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GMTX Gemini Therapeutics	30	43.33 million	37.74 million	Not Optionable
IMVT Immunovant	120	174.32 million	171.18 million	Optionable
MRVI Maravai LifeSciences	610	255.36 million	249.97 million	Optionable
RXRX Recursion Pharmaceuticals	400	434.15 million	397.55 million	Optionable

MRVI, IMVT, GMTX, and RXRX Headlines

Recent News About These Companies

1,912,620 Shares in Recursion Pharmaceuticals, Inc. $RXRX Purchased by Nuveen LLC

August 25 at 3:41 AM | marketbeat.com

Needham Maintains Buy Rating on Recursion (RXRX)

August 24 at 3:29 AM | msn.com

The Next Big Thing: 2 AI-Powered Healthcare Stocks Ready to Explode

August 23 at 4:00 AM | fool.com

Recursion Pharmaceuticals, Inc. $RXRX Stock Position Reduced by Vanguard Group Inc.

August 23 at 3:35 AM | marketbeat.com

Why Recursion Pharmaceuticals Stock Caught a Cold This Week

August 22 at 5:53 PM | fool.com

Recursion Pharmaceuticals (RXRX) Sees Sales And Revenue Growth In Q2 2025

August 22 at 2:13 AM | finance.yahoo.com

Insider Selling: Recursion Pharmaceuticals (NASDAQ:RXRX) Insider Sells 36,599 Shares of Stock

August 21, 2025 | marketbeat.com

Recursion Pharmaceuticals (RXRX) Drops on 3rd Day as Company Execs Dispose of Shares

August 21, 2025 | insidermonkey.com

Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 5.3% - Here's Why

August 20, 2025 | marketbeat.com

Recursion Pharmaceuticals (NASDAQ:RXRX) Insider Najat Khan Sells 36,599 Shares

August 20, 2025 | insidertrades.com

EverSource Wealth Advisors LLC Raises Stake in Recursion Pharmaceuticals, Inc. $RXRX

August 20, 2025 | marketbeat.com

LPL Financial LLC Purchases 57,305 Shares of Recursion Pharmaceuticals, Inc. $RXRX

August 20, 2025 | marketbeat.com

Recursion: "Hold" Rating Based On Initial REC-4881 FAP Treatment Data

August 19, 2025 | seekingalpha.com

Liontrust Investment Partners LLP Lowers Stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

August 18, 2025 | marketbeat.com

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Shares Sold by Vestmark Advisory Solutions Inc.

August 18, 2025 | marketbeat.com

Recursion Pharmaceuticals (RXRX) Expands AI Drug Discovery Pipeline with New Clinical Candid

August 17, 2025 | insidermonkey.com

Analysts Set Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) PT at $7.00

August 16, 2025 | americanbankingnews.com

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Given Consensus Recommendation of "Hold" by Brokerages

August 14, 2025 | marketbeat.com

Recursion Pharmaceuticals: Two Clinical Readouts In H2'25

August 13, 2025 | seekingalpha.com

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Shares Purchased by Blair William & Co. IL

August 12, 2025 | marketbeat.com

Recursion Pharmaceuticals’ Earnings Call Highlights Progress and Challenges

August 11, 2025 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRVI, IMVT, GMTX, and RXRX Company Descriptions

Gemini Therapeutics NASDAQ:GMTX

$60.35 +0.60 (+1.00%)

As of 08/22/2025

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Immunovant NASDAQ:IMVT

$14.90 -0.34 (-2.26%)

Closing price 03:59 PM Eastern

Extended Trading

$14.90 0.00 (-0.01%)

As of 04:04 PM Eastern

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Maravai LifeSciences NASDAQ:MRVI

$2.40 -0.05 (-1.84%)

Closing price 03:59 PM Eastern

Extended Trading

$2.40 0.00 (-0.21%)

As of 04:04 PM Eastern

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.

Recursion Pharmaceuticals NASDAQ:RXRX

$4.84 -0.10 (-1.92%)

Closing price 03:59 PM Eastern

Extended Trading

$4.85 +0.01 (+0.19%)

As of 04:05 PM Eastern

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time